Immunotherapy Shows ‘Striking’ Results in Metastatic Urothelial Cancer

The immune checkpoint inhibitor atezolizumab showed promising, lasting efficacy in patients with locally advanced or metastatic urothelial cancer, according to results of a phase II clinical trial conducted by an international team including Cleveland Clinic Cancer Center oncologist Petros Grivas, MD, PhD. The findings represent the first significant improvement in the systemic treatment of metastatic urothelial cancer in 30 years.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy